Paper39286286
Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation.
Lu W and 5 others. Drug Des Devel Ther, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. Papers, record 39286286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39286286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Hemangioma | Major topic |
| Cell Proliferation | Major topic |
| Drug Screening Assays, Antitumor | Major topic |
| Humans | |
| Infant | |
| Computer Simulation | |
| Apoptosis | |
| Protein Interaction Maps | |
| Drug Repositioning | |
| Dose-Response Relationship, Drug |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29130882 | Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. | Elife | 2017 | https://conductscience.org/library/papers/29130882 | PubMed |
| 2 | 29609830 | Safety data and withdrawal of hepatotoxic drugs. | Therapie | 2021 | https://conductscience.org/library/papers/29609830 | PubMed |
| 3 | 30470818 | Turning foes to friends: targeting cancer-associated fibroblasts. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30470818 | PubMed |
| 4 | 18676554 | Growth characteristics of infantile hemangiomas: implications for management. | Pediatrics | 2008 | https://conductscience.org/library/papers/18676554 | PubMed |
| 5 | 30127393 | Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. | Nat Med | 2018 | https://conductscience.org/library/papers/30127393 | PubMed |
| 6 | 16950977 | Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. | Pediatrics | 2006 | https://conductscience.org/library/papers/16950977 | PubMed |
| 7 | 16199517 | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16199517 | PubMed |
| 8 | 33961406 | Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics. | Chem Res Toxicol | 2021 | https://conductscience.org/library/papers/33961406 | PubMed |
| 9 | 32662682 | β-blocker therapy for infantile hemangioma. | Expert Rev Clin Pharmacol | 2020 | https://conductscience.org/library/papers/32662682 | PubMed |
| 10 | 23199362 | MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. | J Cardiovasc Magn Reson | 2012 | https://conductscience.org/library/papers/23199362 | PubMed |
| 11 | 21995808 | A prospective study of infantile hemangiomas with a focus on incidence and risk factors. | Pediatr Dermatol | 2011 | https://conductscience.org/library/papers/21995808 | PubMed |
| 12 | 6203733 | Drug-induced pulmonary fibrosis. | Environ Health Perspect | 1984 | https://conductscience.org/library/papers/6203733 | PubMed |
| 13 | 18852116 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18852116 | PubMed |
| 14 | 4122362 | A clinical review of bleomycin--a new antineoplastic agent. | Cancer | 1973 | https://conductscience.org/library/papers/4122362 | PubMed |
| 15 | 25521941 | cytoHubba: identifying hub objects and sub-networks from complex interactome. | BMC Syst Biol | 2014 | https://conductscience.org/library/papers/25521941 | PubMed |
| 16 | 25352553 | STRING v10: protein-protein interaction networks, integrated over the tree of life. | Nucleic Acids Res | 2015 | https://conductscience.org/library/papers/25352553 | PubMed |
| 17 | 30425336 | mTOR signalling and cellular metabolism are mutual determinants in cancer. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/30425336 | PubMed |
| 18 | 33068428 | Comparative Toxicogenomics Database (CTD): update 2021. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33068428 | PubMed |
| 19 | 23701395 | Haemangioma: clinical course, complications and management. | Br J Dermatol | 2013 | https://conductscience.org/library/papers/23701395 | PubMed |
| 20 | 22455463 | clusterProfiler: an R package for comparing biological themes among gene clusters. | OMICS | 2012 | https://conductscience.org/library/papers/22455463 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42105055 | Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42105055 | PubMed |
| 41928438 | Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/41928438 | PubMed |
| 41567426 | Topical propranolol for infantile hemangioma: a comprehensive review of mechanisms, clinical efficacy, and novel formulations. | Front Pediatr | 2025 | https://conductscience.org/library/papers/41567426 | PubMed |
| 41256263 | Propranolol (1 mg/kg/day) with intralesional bleomycin versus propranolol monotherapy for infantile hemangioma: a randomized controlled trial. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41256263 | PubMed |
| 41255770 | Machine learning identifies immune-perinatal predictors of infantile hemangioma. | Front Pediatr | 2025 | https://conductscience.org/library/papers/41255770 | PubMed |
| 40428263 | Vulvar Hemangioma: A Review. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40428263 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PRKG1 | 5592 | PubTator's text mining | https://conductscience.org/library/genes/5592 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39286286
GET https://conductscience.org/api/papers/v1/39286286/references?page=2